Catherine J. McNeal, MD, PhD Reference List

UC/MALDI-MS analysis of HDL; evidence for density-dependent post-translational modifications

Available online at www.sciencedirect.com International Journal of Mass Spectrometry 268 (2007) 227 233 UC/MALDI-MS analysis of HDL; evidence for density-dependent post-translational modifications Jeffery

Disclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values

39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

Familial hypercholesterolaemia in children and adolescents

Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease

Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College

行政院國家科學委員會補助專題研究計畫成果報告

NSC892314B002270 898 1 907 31 9010 23 1 Molecular Study of Type III Hyperlipoproteinemia in Taiwan β β ε E Abstract β Type III hyperlipoproteinemia (type III HLP; familial dysbetalipoproteinemia ) is a

Zuhier Awan, MD, PhD, FRCPC

Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier

Hypertriglyceridemia and the Related Factors in Middle-aged Adults in Taiwan

1 Hypertriglyceridemia and the Related Factors in Middle-aged Adults in Taiwan Cheng-Chieh Lin, Tsai-Chung Li 2, Shih-Wei Lai, Kim-Choy Ng 1, Kuo-Che Wang, Chiu-Shong Liu Department of Community Medicine,

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease.

Michael Garshick, MD PGY-1 Columbia University Medical Center Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Study Purpose and Rationale:

References. 1. Personen E, Liuba P. Footprints of atherosclerotic coronary heart disease in children. Rev Port Cardiol 2004;23:

IS FAMILY HISTORY OF PREMATURE CARDIOVASCULAR DISEASES APPROPRIATE FOR DETECTION OF DYSLIPIDEMIC CHILDREN IN POPULATION-BASED PREVENTIVE MEDICINE PROGRAMS? Roya Kelishadi, M.D., Associate Professor and

Lipids Testing

Previously Listed as Edit 12 190.23 - Lipids Testing Lipoproteins are a class of heterogeneous particles of varying sizes and densities containing lipid and protein. These lipoproteins include cholesterol

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia

Management of Hyperlipidaemia in General Practice

Management of Hyperlipidaemia in General Practice Pages with reference to book, From 285 To 287 Waris Qidwai ( Family Medicine Division, Department of Community Health Sciences, The Aga Khan University,

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease

Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,

Deselection 2011 WD Metabolic Diseases/ Nutrition Disorders/Allergies

DISPLAY_CALL_NO TITLE_BRIEF PUB_DATE WD 105 D963m 1988 Magnesium in clinical practice / 1988 WD 105 N976 1984 Nutritional assessment / 1984 WD 105 S855i 1996 Iron nutrition in health and disease / 1996

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients

ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,

Friedewald formula. ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5. Friedewald formula. Friedewald formula

Friedewald formula 1 1 1,2 ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5 Friedewald formula Friedewald formula 2003 99 Friedewald formula Colorimetric method

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,

Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam

Biochemistry Department Plasma lipoproteins & atherosclerosis by Prof.Dr. Maha M. Sallam 1 1. Recognize structures,types and role of lipoproteins in blood (Chylomicrons, VLDL, LDL and HDL). 2. Explain

Acetyl CoA HMG CoA Mevalonate (C6) Dimethylallyl Pyrophosphate isopentenyl Pyrophosphate (C5) Geranyl Pyrophosphate (C10) FarnesylPyrophosphate (C15) Squalene (C30) Lanosterol (C30) 7 Dehydrocholesterol

Do Cholesterol Numbers Really Assess Cardiovascular Risk?

of people at risk for HEART DISEASE are not identified by routine testing. Visit us at www.spectracell.com Do Cholesterol Numbers Really Assess Cardiovascular Risk? Lipoprotein Particle numbers tell the

ASSOCIATION BETWEEN BODY MASS INDEX, LIPID PEROXIDATION AND CORONARY LIPID RISK FACTORS IN HYPOTHYROID SUBJECTS

ASSOCIATION BETWEEN BODY MASS INDEX, LIPID PEROXIDATION AND CORONARY LIPID RISK FACTORS IN HYPOTHYROID SUBJECTS V Shanmugapriya, PK Mohanty, D Anil Kumar Department of Biochemistry, Vinayaka Missions Medical

... CPE/CNE QUIZ... CPE/CNE QUESTIONS

CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing

B. Patient has not reached the percentage reduction goal with statin therapy

Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels

Lipoprotein Subclassification Testing for Screening, Evaluation and Monitoring of Cardiovascular Disease

for Screening, Evaluation and Monitoring of Cardiovascular Disease Last Review Date: June 9, 2017 Number: MG.MM.LA.40Cv2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The

Lipoprotein (a): Is it important for Friedewald formula?

ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry

. Non HDL-c : Downloaded from ijdld.tums.ac.ir at 18:05 IRDT on Friday March 22nd Non HDL LDL. . LDL Non HDL-c

208-23 (2 ) 0 389 -. Non HDL * Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 Non HDL : LDL.. 5 3277 :.. odds ratio Chi-Square %3/9 Non HDL-C %2 LDL-C. %3 : Non-HDL-C LDL-C. (CI

Separation of HDL Particles by Immunoprecipitation

Sun Diagnostics, LLC Separation of HDL Particles by Immunoprecipitation Rae-Anne Nguyen and John H. Contois 13 Introduction We all know that HDL cholesterol concentration is inversely associated with coronary

Lipids Testing

190.23 - Lipids Testing Lipoproteins are a class of heterogeneous particles of varying sizes and densities containing lipid and protein. These lipoproteins include cholesterol esters and free cholesterol,

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

Is Universal Pediatric Lipid Screening Justified? YES Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016 None Disclosures What is a Pediatrician? Pediatrics is the specialty of medical science

Lipid Profiles in Obese Children

Ada Medica et Biologica Vol. 49, R elation of Apolipoprotein E Polymorphism Lipid Profiles in Obese Children T adashi ASAMI1, 'Division of Pediatrics and Dental Sciences, Tatiana CIOMARTEN1, Sueshi Department

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular

The apolipoprotein story

Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date

MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with

High density lipoprotein metabolism

High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee

Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham

Page 1. Disclosures. Background. No disclosures

Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen

Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus

Original Article Nepal Med Coll J 2012; 14(4): 278-282 Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus A

Comparison of Lipoprotein (a) and Apolipoproteins in Children with and without Familial History of Premature Coronary Artery Disease

Short Comunication Iran J Pediatr Jun 2008; Vol 18 ( No 2), Pp:159-162 Comparison of Lipoprotein (a) and Apolipoproteins in Children with and without Familial History of Premature Coronary Artery Disease

STUDY OF SERUM CHOLESTEROL BINDING RESERVE AND CHOLESTEROL LEVELS IN MYOCARDIAL INFARCTION PATIENTS AT TERTIARY CARE HOSPITAL FROM CENTRAL INDIA

Original Research Article Biochemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 STUDY OF SERUM CHOLESTEROL BINDING RESERVE AND CHOLESTEROL LEVELS IN MYOCARDIAL INFARCTION PATIENTS

The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India

eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND

Chapter VIII: Dr. Sameh Sarray Hlaoui

Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.

LDL How Low can (should) you Go and be Safe

LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and

INCREASED SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IS ASSOCIATED WITH A REDUCTION IN PERIPHERAL MONOCYTE COUNT

INCREASED SERUM HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IS ASSOCIATED WITH A REDUCTION IN PERIPHERAL MONOCYTE COUNT IN NORMAL INDIVIDUALS Zei-Shung Huang, 1 Kwan-Lih Hsu, 1 Kuo-Liong Chien, 1 Tien-Chun

Lipoprotein Particle Profile

Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the

Coverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests

Coverage Guidelines NMR LipoProfile and NMR LipoProfile -II Tests Disclaimer: Please note that Baptist Health Plan updates Coverage Guidelines throughout the year. A printed version may not be most up

Best Lipid Treatments

Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES

Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C

Hereditary dyslipidaemias and combined risk factors in children with a family history of premature coronary artery disease

292 Department of Paediatrics, Malmö University Hospital, S-205 02 Malmö, Sweden T Sveger C-E Flodmark K Nordborg Department of Clinical Chemistry, Lund University Hospital, Lund, Sweden P Nilsson-Ehle

Welcome and Introduction

Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien

Lipid Metabolism in Familial Hypercholesterolemia

Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence

Comparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, : Review

European Journal of Environment and Public Health, 2017, 1(1), 04 ISSN: 2468-1997 Comparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, 2011-2014: Review Rasaki Aranmolate

Do Cholesterol Numbers Really Assess Cardiovascular Risk?

of people at risk for HEART DISEASE are not identified by routine testing. Visit us at www.spectracell.com Do Cholesterol Numbers Really Assess Cardiovascular Risk? Lipoprotein Particle numbers tell the

Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care

Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care Purpose Explore the adherence rates to cholesterol treatment targets among patients who seek care

Cholesterol Metabolism

Cholesterol Metabolism Lippincott s Illustrated Review Chapter 18 Steroid Nucleus 1 2 Cholesterol was isolated from gall bladder stones in 1774 3 Sources and Elimination of Cholesterol Synthesis: 1000

Cardiac Disease Screening Lipid Profile

Cardiac Disease Screening Lipid Profile Date of Origin: 04/2003 Last Review Date: 02/27/2019 Effective Date: 03/01/2019 Dates Reviewed: 01/2004, 04/2005, 12/2005, 06/2006, 06/2007, 07/2008, 6/2011, 05/2012,

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital

RECOGNITION OF THE METABOLIC SYNDROME

THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary

Atherosclerotic cardiovascular disease remains the leading

AHA Scientific Statement American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood Rae-Ellen W. Kavey, MD; Stephen R. Daniels, MD, PhD;

LOW BIRTH WEIGHT IS ASSOCIated

PRELIMINARY COMMUNICATION A Large High-Density Lipoprotein Enriched in Apolipoprotein C-I A Novel Biochemical Marker in Infants of Lower Birth Weight and Younger Gestational Age Peter O. Kwiterovich, Jr,

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az

Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of

4 th and Goal To Go How Low Should We Go? :

4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date

MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides

Lipid/Lipoprotein Structure and Metabolism (Overview)

Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date

MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with

Lipoproteins Metabolism

Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical

FoodGate: The break-in, cover-up, and aftermath. Robert H. Lustig, M.D., M.S.L. Cristin Kearns, D.D.S., M.B.A. Laura Schmidt, Ph.D., M.P.H., L.C.S.W.

FoodGate: The break-in, cover-up, and aftermath Robert H. Lustig, M.D., M.S.L. Cristin Kearns, D.D.S., M.B.A. Laura Schmidt, Ph.D., M.P.H., L.C.S.W. Osher Mini Med School for the Public, Mar 6, 2018 Decrease

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health

Normal blood vessels A= artery V= vein

Normal blood vessels A= artery V= vein Artery (A) versus vein (V) ARTERIOSCLEROSIS Arteriosclerosis ="hardening of the arteries" arterial wall thickening and loss of elasticity. Three patterns are recognized,

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:

STATIN UTILIZATION MANAGEMENT CRITERIA

STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy

ORIGINAL ARTICLE. Introduction

Turkish Journal of Endocrinology and Metabolism, (1999) 1 : 23-28 Relationship Between Serum Insulin Levels, Lipoprotein (a) Concentrations and Coronary Artery Disease in Patients with Impaired and Normal

EFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS. Kamsiah Jaarin, Nafeeza MI*

REVIEW ARTICLE Malaysian Journal of Medical Sciences, Vol. 6, No. 2, July 1999 (5-11) EFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS Kamsiah Jaarin,

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry

The leading cause of death in the United States is coronary

Overcoming Inertia: Improvement in Achieving Target Low-density Lipoprotein Cholesterol Kenneth C. Goldberg, MD; Stephanie D. Melnyk, PharmD; and David L. Simel, MD, MHS Objective: To improve lipid management

Submitted to the University of Adelaide for the degree of. Doctor of Science. Robert Vink, BSc (Hons), PhD

Submitted to the University of Adelaide for the degree of Doctor of Science Robert Vink, BSc (Hons), PhD TABLE OF CONTENTS DECLARATION STATEMENT SUPPORTING THE SUBMISSION... 1 Dot Point Summary 1 Detailed

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011

Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled

Tsunetomo, Y. Hagakure. Wilson WS, trans. Tokyo, Japan: Kodansha America Inc; 1716.

High Density Lipoproteins - Do We Have Clue? - Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey, New Jersey Medical School Diplomate

LDL . (LDL) Downloaded from ijdld.tums.ac.ir at 12:38 IRST on Friday February 1st 2019 LDL LDL NCEP-ATP-III (LDL) :

197-207 (2 ) 10 1389 -. 2 1 1* :.. 352 :... (TG). (). -.(r= 0/95) :. TG. NCEP-ATP-III. :. () : -1-2 1593748711 : ronakn2000@yahoo.com : 88942661-5 09124135284 ... : 198.[4]. 1990 -. C.[4]. NCEP.[4]...

Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.

Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management None Disclosures Arthur Agatston Conceptual Approach to CAD Risk Devereux Circulation, 1993 1 Age Obesity Family Hx Diabetes

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

TECHNICAL REPORT OF EFSA

Supporting Publications 2012:305 TECHNICAL REPORT OF EFSA Response to comments on the Scientific Opinion on the substantiation of a health claim related to isolated soy protein and reduction of blood LDLcholesterol